JP2007514005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514005A5 JP2007514005A5 JP2006548049A JP2006548049A JP2007514005A5 JP 2007514005 A5 JP2007514005 A5 JP 2007514005A5 JP 2006548049 A JP2006548049 A JP 2006548049A JP 2006548049 A JP2006548049 A JP 2006548049A JP 2007514005 A5 JP2007514005 A5 JP 2007514005A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- compound
- treatment
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Claims (2)
- 治療上有効量の請求項1記載の化合物と医薬上許容される担体を含む、鼻炎、喘息、または鼻うっ血の予防あるいは治療のための、医薬組成物。
- 治療上有効量の請求項1記載の化合物と医薬上許容される担体を含む、プロスタグランジン D2が関与する疾患の予防あるいは治療のための、医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53029803P | 2003-12-15 | 2003-12-15 | |
PCT/CA2004/002123 WO2005056527A1 (en) | 2003-12-15 | 2004-12-13 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007514005A JP2007514005A (ja) | 2007-05-31 |
JP2007514005A5 true JP2007514005A5 (ja) | 2008-01-24 |
Family
ID=34676897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006548049A Withdrawn JP2007514005A (ja) | 2003-12-15 | 2004-12-13 | 置換テトラヒドロカルバゾールおよびシクロペンタノインドール誘導体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7019022B2 (ja) |
EP (1) | EP1697322A4 (ja) |
JP (1) | JP2007514005A (ja) |
CN (1) | CN1894213A (ja) |
AU (1) | AU2004296910A1 (ja) |
CA (1) | CA2548602A1 (ja) |
WO (1) | WO2005056527A1 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
DK1833791T3 (da) | 2004-12-27 | 2011-10-24 | Actelion Pharmaceuticals Ltd | 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister |
WO2006089309A2 (en) * | 2005-02-17 | 2006-08-24 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
EP1902026B1 (en) | 2005-06-24 | 2010-02-17 | Eli Lilly And Company | Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm) |
EP1916245B1 (en) | 2005-07-22 | 2011-10-26 | Shionogi & Co., Ltd. | Indole derivative having pgd2 receptor antagonist activity |
JP5064219B2 (ja) | 2005-07-22 | 2012-10-31 | 塩野義製薬株式会社 | Pgd2受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
EP1932839A4 (en) | 2005-09-06 | 2014-09-10 | Shionogi & Co | INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR |
US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
AU2007282949B8 (en) | 2006-08-07 | 2012-10-04 | Actelion Pharmaceuticals Ltd. | (3-Amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives |
WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
EP2114154B1 (en) * | 2007-02-08 | 2013-08-28 | Merck Sharp & Dohme Corp. | Method of treating atherosclerosis, dyslipidemias and related conditions |
CL2008000684A1 (es) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
KR101235961B1 (ko) * | 2008-02-01 | 2013-02-21 | 판미라 파마슈티칼스, 엘엘씨 | 프로스타글란딘 d2 수용체의 n,n-이치환 아미노알킬비페닐 길항제 |
GB2460597B8 (en) * | 2008-02-01 | 2014-03-12 | Amira Pharmaceuticals Inc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
US8497381B2 (en) * | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
JP2011518130A (ja) * | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト |
EP2119705A1 (en) * | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
ES2396612T3 (es) | 2008-05-16 | 2013-02-22 | Eli Lilly & Company | Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos |
MX2010012514A (es) * | 2008-05-20 | 2011-05-30 | Cerenis Therapeutics S A | Niacina y un medicamento nsaid para tratamiento combinado. |
US20110144160A1 (en) * | 2008-07-03 | 2011-06-16 | Amira Pharmaceuticals, Inc. | Antagonists of Prostaglandin D2 Receptors |
GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
WO2010057118A2 (en) * | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
JP2013500978A (ja) | 2009-07-31 | 2013-01-10 | パンミラ ファーマシューティカルズ,エルエルシー. | Dp2受容体アンタゴニストの眼の医薬組成物 |
US8815917B2 (en) * | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
JP2013516475A (ja) | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | Dp2アンタゴニストおよびその使用 |
TWI562987B (en) | 2010-03-22 | 2016-12-21 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
EP2697223B1 (en) | 2011-04-14 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
PL3119779T3 (pl) | 2014-03-17 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2 |
JP6484644B2 (ja) | 2014-03-18 | 2019-03-13 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | アザインドール酢酸誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用 |
CN106032383B (zh) * | 2015-03-19 | 2019-08-13 | 中国科学院上海药物研究所 | 一类三环类似物、其制备方法和用途 |
MX2018003202A (es) | 2015-09-15 | 2018-06-08 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
CN112362781A (zh) * | 2020-11-09 | 2021-02-12 | 河北诚信集团有限公司 | 一种甲基亚磺酸钠的含量测定方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL81325A (en) * | 1986-01-23 | 1990-11-29 | Merck Frosst Canada Inc | Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them |
US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
CA1299577C (en) * | 1987-01-09 | 1992-04-28 | John W. Gillard | Tetrahydrocarbazole 1-alkanoic acids |
US20010047027A1 (en) * | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
JP2006528938A (ja) | 2003-05-20 | 2006-12-28 | メルク フロスト カナダ リミテツド | フルオロ−メタンスルホニル置換シクロアルカノインドール、およびプロスタグランジンd2アンタゴニストとしてのこれらの使用 |
DE602004026597D1 (de) | 2003-08-07 | 2010-05-27 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
-
2004
- 2004-12-08 US US11/007,009 patent/US7019022B2/en not_active Expired - Fee Related
- 2004-12-13 EP EP04802298A patent/EP1697322A4/en not_active Withdrawn
- 2004-12-13 AU AU2004296910A patent/AU2004296910A1/en not_active Abandoned
- 2004-12-13 JP JP2006548049A patent/JP2007514005A/ja not_active Withdrawn
- 2004-12-13 CA CA002548602A patent/CA2548602A1/en not_active Abandoned
- 2004-12-13 WO PCT/CA2004/002123 patent/WO2005056527A1/en not_active Application Discontinuation
- 2004-12-13 CN CNA2004800372808A patent/CN1894213A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007514005A5 (ja) | ||
LTC1562603I2 (lt) | Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui | |
JP2008513510A5 (ja) | ||
JP2007501251A5 (ja) | ||
JP2003503454A5 (ja) | ||
EP2305639A3 (en) | Organic compounds | |
JP2010513478A5 (ja) | ||
TWI315204B (en) | Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent | |
JP2006526031A5 (ja) | ||
JP2008539268A5 (ja) | ||
JP2009502743A5 (ja) | ||
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
JP2005518413A5 (ja) | ||
JP2003531118A5 (ja) | ||
JP2010504973A5 (ja) | ||
JP2010526777A5 (ja) | ||
JP2005509503A5 (ja) | ||
JP2003526626A5 (ja) | ||
TWI369988B (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
JP2008516909A5 (ja) | ||
JP2008513426A5 (ja) | ||
JP2010500284A5 (ja) | ||
JP2004532828A5 (ja) | ||
WO2006064228A3 (en) | Thiazolopyramidine compounds for the modulation of chemokine receptor activity | |
JP2008513427A5 (ja) |